TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00810394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
Study: NCT01052922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 sample g-SENSA
Description: Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 sample InSure
Description: Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 sample OC-Micron
Description: Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
Study: NCT04452760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Physical exercise intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testing sessions
Description: Testing sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing sessions
Description: Testing sessions
Study: NCT02146326

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)
Description: BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)
Description: BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
Study: NCT03375528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DES implantation
Description: Coronary artery intervention using Drug eluting stent and Intravascular Ultrasound is performed.
Study: NCT01613560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AI adjuvant therapy
Description: preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI+chemotherapy adjuvant therapy
Description: preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AI adjuvant therapy
Description: preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
Study: NCT02656823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANKYLOS C/X implant A 6.6
Description: Treatment with six (6) 6.6 mm implants and a bridge to restore chewing function of an edentulous maxilla.
Study: NCT02970877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal filtrate from 150 g stool from healthy lean donors
Description: 150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal filtrate from 150 g of the recipient's own stool
Description: 150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
Study: NCT01104116

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-FDG PET/CT imaging
Description: Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
Study: NCT00425802

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: graft-versus-tumor induction therapy
Study: NCT01350310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection
Description: Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracoronary injection
Description: Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramyocardial injection
Description: Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
Study: NCT01315353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Cryotherapy
Description: Participants had cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Electrosurgical Excision Procedure (LEEP)
Description: Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
Study: NCT00425802

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine

Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: OTHER
Intervention: mycophenolate mofetil

Intervention type: PROCEDURE
Group type: OTHER
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation

Intervention type: RADIATION
Group type: OTHER
Intervention: total-body irradiation
Study: NCT00985764

Intervention type: PROCEDURE
Intervention: cesarean delivery
Study: NCT01315353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Electrosurgical Excision Procedure (LEEP)
Description: Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Electrosurgical Excision Procedure (LEEP)
Description: Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
Study: NCT01000285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Study: NCT02662101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exsalt SD7, Exsalt T7 Wound Dressing
Study: NCT04248660

Intervention type: OTHER
Intervention: uterine artery doppler measurement
Description: The effect of delivery type on changes in uterine blood flow will be investigated.~Doppler results groups will be defined according to the effect of deviations in uterine blood flow on neonatal and perinatal results.
Study: NCT04585776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT03622619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimel Antibacterial Manuka+ Dry Eye Drops
Description: Leptospermum sp Honey 165mg/g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra Lubricating Eye Drops
Description: Polyethylene glycol 400 0.4% and propylene glycol 0.3%
Study: NCT03531944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community pharmacist-involved collaborative care
Description: Community pharmacist-involved collaborative care in the management of individuals with type 2 diabetes mellitus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care with physician and as needed visit to the nurse
Study: NCT02936128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TruSkin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound Cover
Study: NCT01108107

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: 130 mg/m2 intravenously on day 1 of a 3-weekly cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: 2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: 130 mg/m2 intravenously on day 1 of a 3-weekly cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: 2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Panitumumab
Description: 9 mg/kg intravenously on day 1 of a 3-weekly cycle
Study: NCT02720367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Description: TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Description: TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
Study: NCT01696942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimzia
Description: 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: mesalamine 800 mg orally three times daily
Study: NCT04816331

Intervention type: OTHER
Intervention: Medical records and clinical measurements
Description: Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling.

Intervention type: OTHER
Intervention: Medical records and clinical measurements
Description: Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling.
Study: NCT01413854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: One tablet two times daily during four weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 50 mg, two times daily (oral adm.) during four weeks
Study: NCT04062968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video education
Description: Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .
Study: NCT00688103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETN Alone
Description: etanercept (25 mg, twice/week, s.c.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETN+MTX
Description: etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
Study: NCT02697994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile Water
Description: 0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dry Injections
Description: dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
Study: NCT02937233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02866500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life survey/ dental statement
Description: Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
Study: NCT01809496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Centered Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Centered Counseling
Study: NCT02502799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Early Intervention
Description: Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Early Intervention
Description: Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Early Intervention
Description: Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Training with Adolescent Cognitive Behavioral Therapy
Description: Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Training with Adolescent Cognitive Behavioral Therapy
Description: Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Adolescents will receive methylphenidate.
Study: NCT04199897

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Succrose rinsing
Description: Sucrose rinsing 7-8 times a day for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Succrose rinsing
Description: Sucrose rinsing 7-8 times a day for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic lozenges
Description: Probiotic lozenges 2 times a day for 35 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges
Description: Probiotic lozenges 2 times a day for 35 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: xylitol rinsing
Description: Xylitol rinsing 7-8 times a day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: xylitol rinsing
Description: Xylitol rinsing 7-8 times a day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo lozenges 2 times a day for 35 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: Placebo lozenges 2 times a day for 35 days
Study: NCT05353946

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Optimal stent expansion by IVUS-guided PCI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Optimal stent expansion by IVUS-guided PCI.
Study: NCT01851954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: IV clarithromycin infusion
Study: NCT00894153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy plus p53
Description: chemotherapy plus p53

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: chemotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy
Study: NCT02330146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCT-01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01377597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study: NCT01416415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video education on proper eye drop instillation technique
Description: The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo video education on healthy eating tips
Description: The video is approximately seven minutes long and teaches tips to promote healthy eating.
Study: NCT02871856

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Low dose CT
Description: low-dose screening CT of chest for lung cancer detection
Study: NCT01149356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given subcutaneously to premenopausal patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given subcutaneously to premenopausal patients
Study: NCT00530907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 5.3 mg/kg by mouth daily x 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 2.5 mg/kg by vein over 90 minutes every 2 weeks
Study: NCT03368469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A is an investigational device manufactured by Soterix Medical, Inc. (New York, NY, USA). It is designed for use in noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes.
Study: NCT03224923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60mg
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: once daily
Study: NCT03439254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (10 mg)
Description: Tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (10 mg to 25 mg)
Description: Tablets administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally once daily.
Study: NCT02334501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib